Skip to main
  1. Stocks
  2. Ovid Therapeutics
  3. Forecast
OVID

Ovid Therapeutics (OVID) Stock Forecast & Price Target

Ovid Therapeutics (OVID) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ovid Therapeutics is attractive because its lead asset OV329 targets a clinically validated epilepsy mechanism, GABA-AT inhibition, but is engineered to avoid vigabatrin’s retinal toxicity and gram-scale dosing burden, with Ph1 data across 68 volunteers showing clean ophthalmology and stronger cortical inhibition than historical vigabatrin at 400-600× lower dose. The investment case is further supported by large unmet need, since 30-40% of the ~3M US epilepsy population continues to seize despite 2+ AEDs, while OV329 could address refractory focal onset seizures and pediatric DEE settings where vigabatrin precedent suggests meaningful commercial opportunity. In addition, Ovid’s KCC2 portfolio adds first-in-class optionality in psychosis, and the balance sheet of $169.8M cash as of June 30, 2026 is expected to fund operations into 2029.

Bears say

Ovid Therapeutics is viewed negatively because its value proposition is highly contingent on a fragile, early-stage epilepsy pipeline that faces major risks from clinical failure, safety or tolerability issues, regulatory delays, and potential new competitors. The bear case suggests the company is effectively a cash shell, with only FY27 net cash and exercise proceeds supporting the $0.58 bear value, while the KCC2 pipeline (OV4071) is assigned no value in any case. With a 20% probability of success across all three indications and a 12% discount rate, the analysis implies that financing risk remains elevated until cash flow turns positive.

Ovid Therapeutics (OVID) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ovid Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Ovid Therapeutics (OVID) Analyst Forecast & Price Prediction

Get the latest Ovid Therapeutics (OVID) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Ovid Therapeutics (OVID)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ovid Therapeutics (OVID) Forecast

Analysts have given Ovid Therapeutics (OVID) a Buy based on their latest research and market trends.

According to 8 analysts, Ovid Therapeutics (OVID) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ovid Therapeutics (OVID)


Ovid Therapeutics (OVID) Analyst Forecast & Price Prediction

Get the latest Ovid Therapeutics (OVID) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Ovid Therapeutics (OVID)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover OVID stock data and trends